Tauns Laboratories, Inc. AI Stock Analysis
Want to see JP:197A full AI Analyst Report?
Tauns Laboratories, Inc. (197A) AI Stock Analysis
Tauns Laboratories, Inc.
(TSE/TYO:197A)
The overall score of 57 reflects a high-risk profile. The primary concern is the severe cash flow deterioration and rising debt, which undermines the company's otherwise strong profitability. While the low P/E ratio and high dividend yield are attractive, they may be value traps if cash generation does not improve. Technicals show a tentative recovery, but the financial foundation is shaky.
Tauns Laboratories, Inc. (197A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 54.37B
- Dividend Yield
- 5.48%
- Average Volume (3M)
- 259.92K
- Price to Earnings (P/E)
- 9.4
- Beta (1Y)
- 0.46
- Revenue Growth
- 7.17%
- EPS Growth
- 38.62%
- Country
- Japan
- Employees
- 271
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Tauns Laboratories, Inc. Business Overview & Revenue Model
Company Description
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an exten...
Tauns Laboratories, Inc. Financial Statement Overview
Summary
Financial performance is mixed. The income statement shows exceptional profitability with a 38.2% net margin, but this is overshadowed by severe cash flow deterioration (negative operating and free cash flow) and rising leverage (debt-to-equity above 1.0). The disconnect between profits and cash generation is a major red flag.
Income Statement
65PositiveBalance Sheet
58NeutralCash Flow
30Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.37B | 14.37B | 18.63B | 18.43B | 15.67B | 17.46B |
| Gross Profit | 8.82B | 8.22B | 12.33B | 12.50B | 8.79B | 14.29B |
| EBITDA | 5.33B | 5.33B | 9.02B | 8.65B | 5.32B | 8.55B |
| Net Income | 5.50B | 5.50B | 6.32B | 5.77B | 3.03B | 4.48B |
Balance Sheet | ||||||
| Total Assets | 44.62B | 44.62B | 36.52B | 29.26B | 18.81B | 20.88B |
| Cash, Cash Equivalents and Short-Term Investments | 3.56B | 3.56B | 9.27B | 9.42B | 1.24B | 6.35B |
| Total Debt | 21.26B | 21.26B | 14.42B | 9.54B | 6.47B | 4.90B |
| Total Liabilities | 25.20B | 25.20B | 19.10B | 15.59B | 10.32B | 13.52B |
| Stockholders Equity | 19.42B | 19.42B | 17.42B | 13.67B | 8.49B | 7.36B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -6.61B | 2.14B | 5.97B | -4.32B | 8.39B |
| Operating Cash Flow | 0 | -2.83B | 6.82B | 9.94B | -3.16B | 10.69B |
| Investing Cash Flow | 0 | -6.18B | -9.26B | -4.11B | -1.62B | -2.68B |
| Financing Cash Flow | 0 | 3.30B | 2.28B | 2.36B | -330.20M | -3.66B |
Tauns Laboratories, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:197A, the sentiment is Positive. The current price of 511.00 is above the 20-day moving average (MA) of 495.85, above the 50-day MA of 506.42, and above the 200-day MA of 495.90, indicating a bullish trend. The MACD of -1.91 indicates Negative momentum. The RSI at 55.36 is Neutral, neither overbought nor oversold. The STOCH value of 55.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:197A.
Tauns Laboratories, Inc. Peers Comparison
Overall Rating
JP:239559Neutral- JP:197A57Neutral
JP:455252Neutral
JP:456952Neutral
JP:454950Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:2395 | 59Neutral | JPY 51.17B | 9.04 | ― | 4.04% | 1.89% | 22.53% |
| JP:197A | 57Neutral | JPY 56.61B | 9.41 | ― | 5.48% | 7.17% | 38.62% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4552 | 52Neutral | JPY 61.01B | -17.93 | ― | 4.01% | 3.05% | -67.53% |
| JP:4569 | 52Neutral | JPY 56.64B | 159.76 | ― | 4.35% | -6.48% | -95.83% |
| JP:4549 | 50Neutral | JPY 73.62B | 40.03 | ― | 2.58% | 3.92% | -52.01% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:197A | Tauns Laboratories, Inc. | 511.00 | 41.47 | 8.83% | |
| JP:2395 | Shin Nippon Biomedical Laboratories, Ltd. | 1239.00 | -281.65 | -18.52% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2250.00 | -71.60 | -3.08% | |
| JP:4552 | JCR Pharmaceuticals Co., Ltd. | 499.00 | -111.29 | -18.24% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1080.00 | -304.25 | -21.98% | |
| JP:368A | Kitazato Corporation | 1278.00 | -182.73 | -12.51% |
Tauns Laboratories, Inc. Corporate Events
TAUNS Announces Kurabo Alliance and Secondary Share Offering
TAUNS Laboratories said its board resolved on November 12, 2026, to enter and execute a capital and business alliance agreement with Kurabo Industries. The agreed cooperation areas include joint life-science product research and development, developm...
TAUNS Reports First-Quarter FY2027 Results
TAUNS Laboratories, listed on the Tokyo Stock Exchange, reported consolidated net sales of ¥3,621 million, operating income of ¥925 million, ordinary income of ¥844 million and net income attributable to owners of the parent of ¥576 million for the t...
Tauns Laboratories to Expand Business Scope and Overhaul Governance Structure
Tauns Laboratories, Inc. plans to amend its Articles of Incorporation to broaden its stated business scope and restructure its governance framework, with shareholder approval and effectiveness both targeted for September 25, 2026. The changes introdu...
Tauns Laboratories Overhauls Governance With New Audit and Supervisory Committee Structure
Tauns Laboratories, Inc. plans to transition from a traditional Board of Corporate Auditors structure to a Company with an Audit and Supervisory Committee, pending approval at its 11th Annual General Meeting of Shareholders on September 25, 2026. The...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026